XML 56 R40.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Commitments and Contingencies (Details Textual) |  | 1 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Feb. 27, 2014 USD ($) | Aug. 28, 2012 USD ($) patients | Jul. 24, 2012 USD ($) | Jun. 15, 2012 USD ($) | Dec. 31, 2007 USD ($) | Dec. 31, 2015 USD ($) | Dec. 31, 2014 USD ($) | Dec. 31, 2013 USD ($) | Dec. 31, 2012 USD ($) | Sep. 30, 2014 USD ($)
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |
Research recorded fees |  |  |  |  |  | $ 13,311,739 | $ 12,267,313 | $ 3,109,331 |  |
Security deposit |  |  |  |  |  |  | 34,733 |  |  |
Letter of credit |  |  |  |  |  |  | 34,733 |  |  |
Manufacturing Agreement [Member] |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |
Project estimated cost for clinical trials of drug Ac-225-HuM195 | $ 5,000,000 |  |  |  |  | 1,500,000 |  |  |  |
Non - refundable institutional fee | $ 600,000 |  |  |  |  |  |  |  |  |
Total project estimated to cost |  |  |  |  |  | 100,000 | 700,000 |  |  |
Research and development costs |  |  |  |  |  | 4,200,000 | 3,600,000 |  |  |
Einstein [Member] |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |
Total project estimated to cost |  |  |  |  |  |  |  |  |  | $ 200,000
Research and development costs |  |  |  |  |  | 100,000 | 100,000 |  |  |
AbbVie Biotherapeutics Corp [Member] | Product Development and Patent License Agreement [Member] |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |
License fee payment |  |  |  |  |  | 3,000,000 |  |  |  |
Milestones payments |  |  |  |  |  | $ 7,750,000 |  |  |  |
Description of royalty payment |  |  |  |  |  | Company shall pay to AbbVie Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire. |  |  |  |
Royalty of net sales percentage |  |  |  |  |  | 12.00% |  |  |  |
First commercial sale period |  |  |  |  |  | 12 years 6 months |  |  |  |
AbbVie Biotherapeutics Corp [Member] | After First Net Sales [Member] |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |
Milestones payments |  |  |  |  |  | $ 1,500,000 |  |  |  |
AbbVie Biotherapeutics Corp [Member] | Phase I Clinical Trial of a licensed product [Member] |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |
Milestones payments |  |  | $ 750,000 |  |  | 750,000 |  |  |  |
Abbott Biotherapeutics Corp [Member] | After First Net Sales [Member] | Product Development and Patent License Agreement [Member] |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |
Net sales in milestones payment |  |  |  |  |  | 10,000,000 |  |  |  |
Oak Ridge National Laboratory [Member] |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  | $ 800,000 | 600,000 | 300,000 |  |
Aptiv Solutions [Member] |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |
Down payment of project estimated cost percentage |  |  |  |  |  | 12.50% |  |  |  |
Down payment for project |  |  |  |  | $ 200,000 | $ 1,900,000 |  |  | $ 200,000 |
Total project estimated to cost |  |  |  |  |  | 2,700,000 |  |  |  |
Research and development costs |  |  |  |  |  | $ 400,000 | 400,000 | 300,000 |  |
Fred Hutchinson Cancer Research Center [Member] | license and sponsored research agreement [Member] |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |
Milestones payments |  |  |  | $ 1,000,000 |  |  |  |  |  |
Description of royalty payment |  |  |  |  |  | Royalty payments of 2% of net sales will be due to FHCRC. |  |  |  |
Royalty of net sales percentage |  |  |  | 2.00% |  |  |  |  |  |
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years ) |  |  |  | $ 200,000 |  |  |  |  |  |
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter ) |  |  |  | 300,000 |  |  |  |  |  |
Research recorded fees |  |  |  |  |  | $ 300,000 | 200,000 | $ 100,000 |  |
Fred Hutchinson Cancer Research Center [Member] | Maximum [Member] | license and sponsored research agreement [Member] |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |
Clinical trial cost for approval of food and drug administration |  |  |  | 23,500,000 |  |  |  |  |  |
Fred Hutchinson Cancer Research Center [Member] | Minimum [Member] | license and sponsored research agreement [Member] |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |
Clinical trial cost for approval of food and drug administration |  |  |  | $ 13,200,000 |  |  |  |  |  |
University of Texas M.D. Anderson Cancer Center [Member] | Clinical Trial Agreement [Member] |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |
Number of Patients | patients |  | 24 |  |  |  |  |  |  |  |
Amount paid to each patient after Completing clinical trial |  | $ 500,000 |  |  |  |  |  |  |  |
Start-up fee for clinical trial |  | $ 33,946 |  |  |  |  |  |  |  |
Start-up due cost paid date |  | Dec. 31, 2015 |  |  |  |  |  |  |  |
Non - refundable institutional fee |  | $ 14,500 |  |  |  |  |  |  |  |
Research recorded fees |  |  |  |  |  | $ 100,000 | $ 0 |  |  |

X
- Definition Amount to be paid for each Patient that has completed the clinical trial. + References No definition available. + Details
Name: | atnm_AmountPaidToEachPatient
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Clinical trial cost for approval of food and drug administration. + References No definition available. + Details
Name: | atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | atnm_CommitmentsAndContingenciesTextualAbstract
Namespace Prefix: | atnm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of royalty payment to related party. + References No definition available. + Details
Name: | atnm_DescriptionOfRoyaltyPaymentToRelatedParty
Namespace Prefix: | atnm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Down payment for project. + References No definition available. + Details
Name: | atnm_DownPaymentForProject
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of total estimated project cost required for down payment. + References No definition available. + Details
Name: | atnm_DownPaymentOfProjectEstimatedCostPercentage
Namespace Prefix: | atnm_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition First commercial sale period. + References No definition available. + Details
Name: | atnm_FirstCommercialSalePeriod
Namespace Prefix: | atnm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fund to related party under agreement after year two. + References No definition available. + Details
Name: | atnm_FundToRelatedPartyUnderAgreementAfterYearTwo
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fund to related party under agreement for first two Year. + References No definition available. + Details
Name: | atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Long term purchase commitment milestones payment. + References No definition available. + Details
Name: | atnm_LongTermPurchaseCommitmentMilestonesPayment
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non refundable institutional fee. + References No definition available. + Details
Name: | atnm_NonRefundableInstitutionalFee
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of patients. + References No definition available. + Details
Name: | atnm_NumberOfPatients
Namespace Prefix: | atnm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Project estimated cost. + References No definition available. + Details
Name: | atnm_ProjectEstimatedCost
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty of net sales percentage. + References No definition available. + Details
Name: | atnm_RoyaltyOfNetSalesPercentage
Namespace Prefix: | atnm_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Start-up due cost paid date. + References No definition available. + Details
Name: | atnm_StartUpDueCostPaidDate
Namespace Prefix: | atnm_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Start-up fee for clinical trial. + References No definition available. + Details
Name: | atnm_StartUpFeeForClinicalTrial
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The current amount of expenditures for a real estate project that has not yet been completed. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.10) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Phase -URI http://asc.fasb.org/extlink&oid=49177889 + Details
Name: | us-gaap_DevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.16) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.16) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19, 20, 22 -Article 5 + Details
Name: | us-gaap_LineOfCredit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585 + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8,17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_SecurityDeposit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | atnm_AgreementAxis=atnm_ManufacturingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | atnm_AgreementAxis=atnm_AlbertEinsteinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_AbbviewBiotherapeuticsCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | atnm_AgreementAxis=atnm_ProductDevelopmentAndPatentLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=atnm_AfterFirstNetSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=atnm_PhaseFirstClinicalTrialOfLicensedProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_AbbottBiotherapeuticsCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_OakRidgeNationalLaboratoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_AptivSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_FredHutchinsonCancerResearchCenterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | atnm_AgreementAxis=atnm_LicenseAndSponsoredResearchAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_UniversityOfTexasMDAndersonCancerCenterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | atnm_AgreementAxis=atnm_ClinicalTrialAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |